BioNexus Gene Lab Corp. Proceeds from Sale of Investment Projects
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from Sale of Investment Projects of $6.39 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfInvestmentProjects · last filed 2022-04-06
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for the quarter ending 2021-12-31 was -$22.00, a 100.52% decline year-over-year.
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for the quarter ending 2021-09-30 was -$52.00.
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for the quarter ending 2020-12-31 was $4.20K.
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for the quarter ending 2020-09-30 was -$227.00.
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for fiscal 2021 was $6.39K, a 78.74% decline from fiscal 2020.
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for fiscal 2020 was $30.06K.
- BioNexus Gene Lab Corp. proceeds from sale of investment projects for fiscal 2019 was $0.00.
| Period end | Proceeds from Sale of Investment Projects 3 month | Proceeds from Sale of Investment Projects 6 month | Proceeds from Sale of Investment Projects 9 month | Proceeds from Sale of Investment Projects 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$22.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | -$74.00 derived: sum of 2 quarters · filed 2022-04-06 | $6.39K 10-K · filed 2022-04-06 | |
| 2021-09-30 | -$52.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $6.41K 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $6.47K 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $4.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | $3.97K derived: sum of 2 quarters · filed 2022-04-06 | $30.06K 10-K · filed 2022-04-06 | |
| 2020-09-30 | -$227.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $25.86K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $26.09K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |